Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1288-8240 | Other Identifier | WHO |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Regeneron Pharmaceuticals | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a prospective, 18-month observational study of adult, adolescent and pediatric Canadian participants with Atopic Dermatitis (AD) commonly known as Eczema, who receive treatment with Dupixent for moderate-to-severe AD (msAD) according to the Canadian-specific prescribing information (in accordance with the Canadian Dupixent Product Monograph). The study will be conducted in approximately 30 centers in Canada to assess participants of all ethnicities and races. At each participating site, all AD participants who receive an initial prescription for Dupixent will be invited to participate in this study, until the Canadian enrollment goal is achieved.
The duration of the study for each participant will be of 18 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with msAD | Canadian msAD participants (ages 6+) who receive Dupixent for msAD according to the Canadian-country specific prescribing information (in accordance with the Canadian Dupixent Product Monograph) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of participants achieving a reduction in Eczema Area and Severity Index (EASI) of at least 75% at 6 months | EASI is a validated measure used to assess the severity and extent of AD. Four AD disease characteristics [erythema, thickness (induration, papulation, and edema), scratching (excoriation), and lichenification] will each be assessed for severity by the Investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage of each body area assessed: head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0 (0%), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Total score is the sum of all subscores. EASI is a composite index with scores ranging from 0 to 72. Higher scores indicates worse condition. Data will be assessed to understand real-world effectiveness of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD using EASI score. | Month 6 |
| Percentage of participants achieving a reduction in EASI of at least 75% at 12 months | EASI is a validated measure used to assess the severity and extent of AD. Four AD disease characteristics [erythema, thickness (induration, papulation, and edema), scratching (excoriation), and lichenification] will each be assessed for severity by the Investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage of each body area assessed: head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0 (0%), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Total score is the sum of all subscores. EASI is a composite index with scores ranging from 0 to 72. Higher scores indicates worse condition. Data will be assessed to understand real-world effectiveness of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD using EASI score. | Month 12 |
| Percentage of participants achieving a reduction in EASI of at least 75% at 18 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in EASI score | Four AD disease characteristics [erythema, thickness (induration, papulation, and edema), scratching (excoriation), and lichenification] will each be assessed for severity by the Investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage of each body area assessed: head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0 (0%), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Total score is the sum of all subscores. EASI is a composite index with scoresEASI is a composite index with scores ranging from 0-72. Higher scores indicate worse conditions. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Canadian msAD participants (ages 6+) who receive Dupixent for msAD according to the Canadian-country specific prescribing information (in accordance with the Canadian Dupixent Product Monograph)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Sciences & Operations | Sanofi | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Investigational Site Number : 1240019 | Calgary | Alberta | T2J 7E1 | Canada | ||
| Investigational Site Number : 1240021 |
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
EASI is a validated measure used to assess the severity and extent of AD. Four AD disease characteristics [erythema, thickness (induration, papulation, and edema), scratching (excoriation), and lichenification] will each be assessed for severity by the Investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage of each body area assessed: head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0 (0%), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Total score is the sum of all subscores. EASI is a composite index with scores ranging from 0 to 72. Higher scores indicates worse condition. Data will be assessed to understand real-world effectiveness of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD using EASI score.
| Month 18 |
| From baseline to 6 months, 12 months, and 18 months post- Dupixent initiation |
| Change from baseline in Body Surface Area of Atopic Dermatitis Involvement (BSA) score | BSA affected by AD disease will be assessed for each major section of the body (head, neck, anterior trunk, back, upper limbs, lower limbs, and genitals). It will be reported as a percentage of all major body sections combined. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD. | From baseline to 6 months, 12 months, and 18 months post- Dupixent initiation |
| Change from baseline in Hospital Anxiety and Depression Scale (HADS) score | HADS is a 14-item scale, with 7 items relating to anxiety and 7 relating to depression. Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. The total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher nxiety/depression complains. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD. | From baseline to 6 months, 12 months, 18 months post-Dupixent initiation |
| Change from baseline in Skin pain/soreness numerical rating scale (NRS) | Skin pain NRS is a simple assessment tool asking participants to rate their skin pain or soreness using a 0 (No pain or soreness) to 10 (worst possible pain or soreness) NRS. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD. | From baseline to 6 months, 12 months, 18 months post-Dupixent initiation |
| Change from baseline in skin feeling hot or burning NRS | Skin burning NRS is a simple assessment tool asking participants to rate the sensation of their skin feeling hot or burning sensation using a 0 (Not feeling hot at all) to 10 (feeling extremely hot) NRS. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD. | From baseline to 6 months, 12 months, 18 months post-Dupixent initiation |
| Change from baseline in Peak Pruritus NRS (PP-NRS) | The peak pruritus NRS is a simple assessment tool asking participants to rate the intensity of their pruritis (itch) using a 0 (no itch) to 10 (worst possible itch) NRS. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD. | From baseline to 6 months, 12 months, 18 months post-Dupixent initiation |
| Percentage of participants with Adverse Events (AEs) or Serious Adverse Events (SAEs) | From baseline up to 18 months post-Dupixent initiation |
| Reasons for discontinuation of Dupixent therapy | Data will be assessed to understand the real-world safety of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD | From baseline up to 18 months post-Dupixent initiation |
| Mean time to Dupixent discontinuation | Data will be assessed to understand the real-world safety of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD | From baseline up to 18 months post-Dupixent initiation |
| Median time to Dupixent discontinuation | Data will be assessed to understand the real-world safety of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD | From baseline up to 18 months post-Dupixent initiation |
| Percentage of participants who initiated Dupixent and remained on treatment | Data will be assessed to understand the real-world safety of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD | At 3 months, 6 months, 12 months and 18 months post- Dupixent initiation |
| Disease characteristics at baseline: EASI score | EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent. Four AD disease characteristics - erythema, thickness (induration, papulation, and edema), scratching (excoriation), and lichenification - will each be assessed for severity by the Investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage of each body area assessed: head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0 (0%), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Total score is the sum of all subscores. EASI is a composite index with scores. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent. | At baseline |
| Disease characteristics at baseline: BSA score | BSA affected by AD disease will be assessed for each major section of the body (head, neck, anterior trunk, back, upper limbs, lower limbs, and genitals). It will be reported as a percentage of all major body sections combined. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent. | At baseline |
| Disease characteristics at baseline: Time between diagnosis and Dupixent prescription | Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent. | At baseline |
| Change from baseline in sleep Disturbance NRS scores post-Dupixent initiation | Participants will be asked to report the severity of their sleep disturbance during the past 7 days using a 0 (sleep not disturbed at all) to 10 (sleep extremely disturbed) NRS. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent. | From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation |
| Change from baseline in the dermatology life quality index (DLQI)/the Children's Dermatology Life Quality Index (CDLQI) scores post-Dupixent initiation | The DLQI and CDLQI are a 10-item validated questionnaire to assess the impact of AD disease on quality of life (QoL) in adults and adolescents/pediatrics, respectively. The rating scale range from 0 (not at all) to 3 (very much) 10 items, which assess QoL over the past week. The total score is the sum of all 10-items ranging from 0 to 30; a high score is indicative of a poor QoL. The CDLQI will be used for adolescent participants (aged ≥ 12 to < 18 years) and pediatric participants (aged ≥ 6 to < 12 years); these participants will switch to the DLQI when they turn 18 years of age (if this happens during the study). The CDLQI will be completed with help from participant's caregivers. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent. | From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation |
| Change from baseline in Work Productivity and Activity Impairment Questionnaire for AD (WPAI-AD) scores post-Dupixent initiation | WPAI-AD is designed to assess the impact of AD disease on the participant's productivity. It is a 6-item validated questionnaire to measure effect of your AD disease on your ability to work and perform regular activities over a 7-day recall period. The questionnaire ask participants to recall following types of activities during the previous 7 days: absenteeism (time missed), presenteeism (impairment/ reduced effectiveness), productivity, and activity impairment. Total WPAI-AD outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Caregivers complete the questionnaire for affected children. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent. | From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation |
| Change from baseline in Work Productivity and Activity Impairment Questionnaire+Classroom Impairment Questions for AD (WPAI-CIQ-AD) scores post-Dupixent initiation | WPAI-CIQ-AD is designed to asses the impact of AD disease on the participant's productivity. It is a 9-item validated questionnaire to measure participants ability to work, attend classes, and perform regular daily activities during the previous 7 days. Participants are asked to report the work time or classes lost due to AD disease; the impact of eczema on the performance in the workplace, at school, or during university classes; the effect of eczema on other daily activities during the previous 7 days. Total WPAI-AD outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Caregivers complete the questionnaire for affected children. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent. | From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation |
| Change from baseline in Dermatitis Family Impact (DFI) score post-Dupixent initiation | DFI is a 10-question disease-specific measure to assess the impact of AD disease on the QoL of the parents and family members of affected children (≥ 6 to < 18 years)'. The DFI is calculated by summing the score of each question with a maximum total score of 30 (higher scores indicate higher impact on life of family). Caregivers complete the questionnaire for affected children. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent. | From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation |
| Concomitant treatments received | Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent | From baseline up to 18 months |
| Dupixent dosing regimen | Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent | From baseline up to 18 months |
| Most commonly used Dupixent dosing regimens | Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent | From baseline up to 18 months |
| Dupixent treatment duration | Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent | From baseline up to 18 months |
| Number of gaps in Dupixent treatment | Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent | From baseline up to 18 months |
| Longest gap in Dupixent treatment | Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent | From baseline up to 18 months |
| Number of missed Dupixent doses over 18 months per participant | Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent | From baseline up to 18 months |
| AD treatments to which participants switch when discontinuing dupixent | Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent | From baseline up to 18 months |
| Reasons for initiation of new AD treatments | Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent | From baseline up to 18 months |
| Reasons for discontinuation and/or switching AD treatments | Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent | From baseline up to 18 months |
| Change from baseline in HADS | HADS is a 14-item scale, with 7 items relating to anxiety and 7 relating to depression. Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. The total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher nxiety/depression complains. Data will be assessed to understand patterns and/or changes in non-atopic conditions in Canadian msAD participants who initiate treatment with Dupixen. | From baseline to 6 months, 12 months and 18 months post- Dupixent initiation |
| Change from baseline in sleep disturbance NRS scores post-Dupixent initiation | Participants will be asked to report the severity of their sleep disturbance during the past 7 days using a 0 (sleep not disturbed at all) to 10 (sleep extremely disturbed) NRS. Data will be assessed to understand patterns and/or changes in non-atopic conditions in Canadian msAD participants who initiate treatment with Dupixent. | From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation |
| Change from baseline in height | Data will be assessed to understand patterns and/or changes in non-atopic conditions in Canadian msAD participants who initiate treatment with Dupixent | From baseline to 6 months, 12 months and 18 months post- Dupixent initiation |
| Change from baseline in weight | Data will be assessed to understand patterns and/or changes in non-atopic conditions in Canadian msAD participants who initiate treatment with Dupixent | From baseline to 6 months, 12 months and 18 months post- Dupixent initiation |
| Change from baseline in BMI | Data will be assessed to understand patterns and/or changes in non-atopic conditions in Canadian msAD participants who initiate treatment with Dupixent | From baseline to 6 months, 12 months and 18 months post- Dupixent initiation |
| Number of participants with demographic characteristics | Data will be assessed for all demographic characteristics by age, sex, race and ethnicity, location to understand baseline characteristics and/or changes in Canadian msAD participants who initiate treatment with Dupixent, with co-existing type 2 inflammatory diseases. | From baseline up to 18 months |
| Calgary |
| Alberta |
| T3B 6A8 |
| Canada |
| Investigational Site Number : 1240009 | Edmonton | Alberta | T5J 3S9 | Canada |
| Investigational Site Number : 1240007 | Edmonton | Alberta | T5K 1X3 | Canada |
| Investigational Site Number : 1240028 | Nanaimo | British Columbia | V9V 1A3 | Canada |
| Investigational Site Number : 1240010 | Surrey | British Columbia | V3R 6A7 | Canada |
| Investigational Site Number : 1240029 | Winnipeg | Manitoba | R3M 3Z4 | Canada |
| Investigational Site Number : 1240026 | Fredericton | New Brunswick | E3B 1G9 | Canada |
| Investigational Site Number : 1240020 | Halifax | Nova Scotia | B3H 4R2 | Canada |
| Investigational Site Number : 1240002 | Ajax | Ontario | L1S 7K8 | Canada |
| Investigational Site Number : 1240024 | Barrie | Ontario | L4M 7G1 | Canada |
| Investigational Site Number : 1240031 | Cobourg | Ontario | K9A 0Z4 | Canada |
| Investigational Site Number : 1240011 | Etobicoke | Ontario | M8X 1Y9 | Canada |
| Investigational Site Number : 1240016 | London | Ontario | N6A 5R9 | Canada |
| Investigational Site Number : 1240025 | Newmarket | Ontario | L3Y 5G8 | Canada |
| Investigational Site Number : 1240008 | Peterborough | Ontario | K9J5K2 | Canada |
| Investigational Site Number : 1240005 | Richmond Hill | Ontario | L4E 4L6 | Canada |
| Investigational Site Number : 1240033 | Toronto | Ontario | M3B 0A7 | Canada |
| Investigational Site Number : 1240030 | Toronto | Ontario | M4E 1R7 | Canada |
| Investigational Site Number : 1240015 | Toronto | Ontario | M5G 1E2 | Canada |
| Investigational Site Number : 1240014 | Toronto | Ontario | M5G 1X8 | Canada |
| Investigational Site Number : 1240018 | Waterloo | Ontario | N2J 1C4 | Canada |
| Investigational Site Number : 1240034 | Whitby | Ontario | L1N 8M7 | Canada |
| Investigational Site Number : 1240012 | Montreal | Quebec | H3H 2R9 | Canada |
| Investigational Site Number : 1240017 | Montreal | Quebec | H3T 1C5 | Canada |
| Investigational Site Number : 1240006 | Pointe-Claire | Quebec | H9R 5M7 | Canada |
| Investigational Site Number : 1240023 | Saint-Jean-sur-Richelieu | Quebec | J3A 1B5 | Canada |
| Investigational Site Number : 1240003 | Regina | Saskatchewan | S4V 1R9 | Canada |
| Investigational Site Number : 1240027 | Saskatoon | Saskatchewan | S7K 2C1 | Canada |
| Investigational Site Number : 1240013 | Québec | G1W 4R4 | Canada |